VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.

Abstract

An evaluation was carried out of the efficacy and toxicity of a novel weekly palliative chemotherapy regimen comprising vincristine, epirubicin and dexamethasone (VEDex) in 57 patients with non-Hodgkin's lymphoma (NHL) treated at this centre. The age range was 34-88 years and the median age was 67 years. Twenty-three patients (40%) had low grade disease and… (More)

Topics

Cite this paper

@article{Helw2000VEDexE, title={VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.}, author={L M El Helw and Paul C Lorigan and Martin Robinson and R. Edward Coleman and Barry Hancock}, journal={International journal of oncology}, year={2000}, volume={16 4}, pages={777-82} }